LENSAR® Revolutionizes Cataract Treatment with ALLY® System: A Game Changer for Ophthalmology Groups

The adoption of the ALLY System by multiple ophthalmology groups signals the appreciation for this cutting-edge technology. LENSAR, Inc., a global medical technology company, has successfully installed the ALLY Systems in five private equity-owned (PE-owned) ophthalmology groups, including EyeSouth Partners' network. This collaboration demonstrates the increasing interest in the ALLY System's procedure speed and operational efficiency.

Private equity-owned ambulatory surgical centers (ASCs) have claimed 14% of the cataract surgical market in the United States. The ALLY System presents an exciting opportunity for these groups, offering numerous advantages over legacy cataract treatment technologies. By partnering with these groups, LENSAR can bring the benefits of the ALLY System to a broader group of surgeons and patients early in the launch cycle.

The ALLY System has received high praise from surgeons who have experienced its benefits firsthand. Matthew B. Kaufman, M.D., Managing Partner of North Georgia Eye Associates, an EyeSouth Practice in Gainesville, GA, attests to the enhanced accuracy and better outcomes the ALLY System has brought to his cataract surgeries. The integrated pre-op data and imaging, along with automated features like cataract density grading and toric IOL alignment tools, have ensured precise placement of each lens.

Meanwhile, Jack M. Chapman, Jr., M.D., Managing Partner of North Georgia Eye Associates and EyeSouth Physician Advisory Board Co-Chair, notes the efficiency of performing a sterile procedure with the ALLY System. The procedure, which takes only one to two minutes, has significantly improved the patient experience compared to the traditional eight to ten-minute procedure.

The impact of the ALLY System extends beyond EyeSouth Partners. Other notable PE-owned ASCs, including US Eye, Eye Health America, Vision Innovation Partners, and Eyecare Partners, have also embraced the ALLY System, further solidifying its position as a game changer in the field of ophthalmology.

About LENSAR

LENSAR is a leading medical device company specializing in the treatment of cataracts and the management of visually significant astigmatism. The company's flagship product, the ALLY Adaptive Cataract Treatment System, integrates proprietary imaging and software with an ultra-fast dual-pulse femtosecond laser. This advanced system allows for the entire cataract procedure to be performed in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead costs. LENSAR's Streamline software technology guides surgeons to achieve better outcomes, revolutionizing cataract surgery.

About EyeSouth Partners

EyeSouth Partners, based in Atlanta, GA, is a management services organization dedicated to building a premier network of eye care services across the United States. The organization partners with leading physicians who share a commitment to providing high-quality medical and surgical specialty eye care. With over 295 doctors and 170 locations across several states, EyeSouth supports its affiliated practices and physician partners with strategic guidance, administrative resources, operating expertise, and capital, all while maintaining a patient-first culture. Backed by Olympus Partners, a private equity firm, EyeSouth continues to expand its network of eye care services throughout the country.

In conclusion, the adoption of LENSAR's ALLY System by multiple PE-owned ophthalmology groups showcases the system's superiority in cataract treatment. The ALLY System's procedure speed, operational efficiency, and precise outcomes have garnered widespread praise within the medical community. As private equity-owned ASCs continue to gain market share, the ALLY System remains well-positioned to transform cataract surgery and deliver exceptional results for surgeons and patients alike.